Since 2012, AVAC has worked to strengthen the capacity of journalists to report on HIV prevention research and global health and science topics. Through its flagship Media Science Café Program, AVAC partners with health media associations in Kenya, Malawi, Tanzania, Uganda, Zambia and Zimbabwe to connect journalists with subject matter experts—researchers, policymakers and advocates—and help build the relationships needed to foster accurate and informed reporting of HIV, COVID and emerging health and science issues.
Media Science Cafes
AVAC Capability Statement
How Do mRNA-Based COVID-19 Vaccines Work?
A detailed graphic showing the biological mechanisms by which mRNA vaccines work. Excerpted From the Lab to Jab series.
Getting the COVID-19 Vaccines We Need
As of March 2023, the World Health Organization reported that there are 199 COVID-19 vaccines in pre-clinical development, and 183 in clinical trials. Most are injectable; but 16 candidates are intranasal, 5 are oral, 2 are inhalable, and 1 is an aerosol.
The Architecture for Pandemic Prevention, Preparedness, & Response (PPPR): Views from Civil Society Leaders on the UN High Level Meetings (Guest Essay)
AVAC’s Executive Director along with partners from the Coalition of Advocates for Global Health and Pandemic Preparedness penned an essay to make the case of meaningful investment in Pandemic Preparedness while referencing continued failures of the COVID-19 pandemic. Read the full essay here.
Experimental Medicine Vaccine Trials (EMVTs): Opportunities and Challenges
In 2023, AVAC and CASPR partners cast a spotlight on many issues and opportunities for HIV vaccine science. This one-pager highlights key conversations.
Status Updates on Ongoing and Planned HIV Prevention Trials
The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.
How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.
Ongoing Studies for the Treatment and Prevention of the COVID-19 Virus
This table is a work in progress, as this is an incredibly dynamic landscape. Over the past month, the scientific community has accelerated development of COVID-19 diagnostics, therapeutics and a potential vaccine. This document also links to a number of resources available to track these developments.
In addition, a collaborative project of the COVID-19 Working Group NY, the PrEP4All Collaboration and Treatment Action Group offers concise overviews and analyses of key research areas.
COVID-19 Resources for Advocates
This document is to help advocates with links to the latest information about COVID-19, including information on its prevention, transmission, relationship to HIV and research that’s underway. Many of the links below are constantly updated so please click through for the latest.
Global Fund Investment Case: Seventh replenishment 2022 executive summary
The Global Fund’s analysis of the economic case for increased investment and commitment to its strategy pandemic preparedness and ending HIV, TB and malaria.
Global Fund Key Numbers and Messages
Key messages and numbers to advocate for full funding of the Global Fund.